Merck (MRK) said Friday it has closed the exclusive global license agreement for LM-299, an investigational PD-1/VEGF bispecific antibody, from LaNova Medicines.
As previously announced, Merck will develop, manufacture and commercialize LM-299.
Merck said it will record a pre-tax charge of $588 million, or about $0.18 per share, in Q4 results related to the upfront payment.
LaNova is also eligible for up to $2.7 billion in milestone payments tied to the technology transfer, development, regulatory approval, and commercialization of LM-299 across multiple indications, including $300 million upon technology transfer anticipated to be completed in 2025, Merck said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。